pre-IPO PHARMA

COMPANY OVERVIEW

Renovacor is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Renovacor’s therapeutic focus is initially on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy. For more information, please visit www.renovacor.com. No part of Renovacor’s website is incorporated by reference into or otherwise deemed to be a part of this press release. Renovacor previously announced that it had entered into a merger agreement with Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) (“CHAQ”), a special purposes acquisition company. Completion of the proposed merger is subject to approval by the stockholders of CHAQ and certain other conditions. The proposed merger is expected to close in the third quarter of 2021.


LOCATION

  • Philadelphia, PA, USA

  • THERAPEUTIC AREAS

  • Cardiovascular Disease

  • WEBSITE

    https://renovacor.com/


    CAREER WEBSITE

    https://renovacor.com/contact-us/


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Sep 2, 2021

    Renovacor, Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange


    Jul 19, 2021

    Renovacor Announces the Appointment of Elizabeth White, Ph.D., as Chief Business Officer and Senior Vice President of Operations


    Jul 12, 2021

    Renovacor Announces the Appointment of Jiwen Zhang, Ph.D., as Senior Vice President, Regulatory Affairs and Quality Assurance


    Jun 29, 2021

    Renovacor Announces the Appointments of Joan Lau, Ph.D., and Gregory F. Covino to its Board of Directors


    Jun 2, 2021

    Renovacor Announces the Appointment of Marc Semigran, M.D., as Chief Medical Officer


    For More Press Releases


    Google Analytics Alternative